A new research center at the University of Virginia is setting out to tackle one of the biggest hurdles in modern medicine: delivering gene therapies precisely where they are needed without causing unwanted side effects.
The Suri Center for Gene Therapy, housed within UVA’s Paul and Diane Manning Institute of Biotechnology, will bring together the university’s strengths in genetic research, nanotechnology, RNA science and focused ultrasound technology. The goal, according to UVA, is to accelerate the development of safer and more effective treatments for a range of complex diseases and move them from the lab to patients more quickly.
The center is being established through a gift from Vishal and Anubha Suri, who said they hope to turn promising genetic discoveries into real treatments that improve patients’ lives. UVA reported that the investment will strengthen research into conditions including pediatric epilepsy, inherited heart disease, cancer and neurodegenerative diseases.
Gene therapy holds the promise of correcting or replacing faulty genes that cause disease, but delivering those genetic instructions to the right cells in the body — and only those cells — remains a major scientific challenge. Current methods can trigger immune responses or affect healthy tissue, limiting their use. The new center aims to draw on UVA’s expertise in targeted drug delivery and biomedical research to overcome those obstacles.
For university students, particularly those studying biomedical engineering, genetics, pharmacology or medicine, the center represents a growing field of interdisciplinary research that combines molecular biology with cutting-edge delivery technologies. Students at UVA may find opportunities for research placements, internships or coursework connected to the center’s work, and those at other institutions may see similar interdisciplinary gene therapy centers emerging as a model for future medical research.
The center is part of a broader push at UVA to accelerate the translation of basic science into clinical applications. The Manning Institute of Biotechnology, which houses the new center, was itself established to bridge the gap between laboratory discoveries and patient treatments.
According to UVA, the Suri Center will focus on developing therapies that can be delivered with greater precision, reducing the risk of side effects while improving outcomes. The university said the center will also work to speed up the timeline from discovery to clinical use, a process that traditionally takes years or even decades.
While the announcement did not specify a timeline for when specific treatments might reach clinical trials, the center’s creation signals a significant institutional commitment to gene therapy research. UVA has a track record in genetic research, including work on RNA-based therapies and focused ultrasound, a technology that uses sound waves to target drugs to specific tissues.
The center’s work could eventually affect how a wide range of diseases are treated, but for now, it is in the early stages of bringing together researchers and resources. Students and researchers interested in the field should watch for updates on research collaborations, funding opportunities and potential clinical trials emerging from the center in the coming years.